A single‑office experience of day‑case water vapor thermal therapy for benign prostatic hyperplasia

Okabe,Takashi

doi:10.3892/wasj.2024.249

A single‑office experience of day‑case water vapor thermal therapy for benign prostatic hyperplasia

Authors:
- Takashi Okabe
View Affiliations

Affiliations: Mizuhodai Urology, Medical Corporation Koshinkai, Fujimi, Saitama 354‑0015, Japan
Published online on: June 4, 2024 https://doi.org/10.3892/wasj.2024.249
Article Number: 34
Copyright : © Okabe . This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to clarify the feasibility, safety and efficacy of day‑case water vapor thermal therapy (WVTT) using the Rezum system in an office‑based setting. The present retrospective study included the data of 40 patients who underwent WVTT performed by a single surgeon at a single‑unit urology clinic from March, 2023 to January, 2024, including 11 patients with complete urinary retention. The present study analyzed the operation time and hospitalization time on the day of the procedure. The International Prostate Symptom Score‑Quality of Life (IPSS‑QOL), post‑void residual (PVR) volume, prostate volume (PV), medication use and adverse events (AEs) were monitored at baseline, and at 1, 2 and 3 months following treatment. All interventions were performed within a median period of 4.0 min (interquartile range (IQR), 2.0‑11.0). The mean hospitalization time on the day of the procedure was 274.8±53.8 (standard deviation) min. Furthermore, the patients exhibited significant improvements in their QOL based on their IPSS‑QOL scores. The PV and PVR volumes decreased significantly. Of the 40 patients, 39 (97.5%) voided spontaneously and were catheter‑free at a median period of 12.0 days (IQR, 6.0‑87.0) following the procedure. Benign prostatic hyperplasia medications were discontinued in 26 of the 40 (65%) patients. The median time to discontinuation was 58.0 days (IQR, 24.0‑114.0). A history of urinary retention and more than six injections during a procedure were found to increase the risk of prolonged post‑operative catheterization. Of the 40 patients, AEs were observed in 11 patients, including grade II gross hematuria in 2 patients (5%). On the whole, the present study demonstrated that day‑case WVTT is feasible, effective and safe as an office‑based, outpatient procedure.

View Figures

View References

1	Vuichoud C and Loughlin KR: Benign prostatic hyperplasia: Epidemiology, economics and evaluation. Can J Urol. 22 (Suppl 1):S1–S6. 2015.PubMed/NCBI
2	Wei JT, Calhoun E and Jacobsen SJ: Urologic diseases in America project: Benign prostatic hyperplasia. J Urol. 173:1256–1261. 2005.PubMed/NCBI View Article : Google Scholar
3	Zhang SJ, Qian HN, Zhao Y, Sun K, Wang HQ, Liang GQ, Li FH and Li Z: Relationship between age and prostate size. Asian J Androl. 15:116–120. 2013.PubMed/NCBI View Article : Google Scholar
4	Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ and McVary KT: Surgical Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. J Urol. 202:592–598. 2019.PubMed/NCBI View Article : Google Scholar
5	Friedl A, Schneeweiss J, Stangl K, Mühlstädt S, Zachoval R, Hruby S, Gründler T, Kivaranovic D, Fornara P, Lusuardi L and Brössner C: The adjustable transobturator male system in stress urinary incontinence after transurethral resection of the prostate. Urology. 109:184–189. 2017.PubMed/NCBI View Article : Google Scholar
6	Brassetti A, DE Nunzio C, Delongchamps NB, Fiori C, Porpiglia F and Tubaro A: Green light vaporization of the prostate: Is it an adult technique? Minerva Urol Nefrol. 69:109–118. 2017.PubMed/NCBI View Article : Google Scholar
7	Checcucci E, Veccia A, De Cillis S, Piramide F, Volpi G, Amparore D, Pecoraro A, Piana A, Granato S, Verri P, et al: New ultra-minimally invasive surgical treatment for benign prostatic hyperplasia: A systematic review and analysis of comparative outcomes. Eur Urol Open Sci. 33:28–41. 2021.PubMed/NCBI View Article : Google Scholar
8	Jones P, Rai BP, Nair R and Somani BK: Current status of prostate artery embolization for lower urinary tract symptoms: Review of world literature. Urology. 86:676–681. 2015.PubMed/NCBI View Article : Google Scholar
9	Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ and Somani BK: Medium-term Outcomes of Urolift (Minimum 12 Months Follow-up): Evidence from a systematic review. Urology. 97:20–24. 2016.PubMed/NCBI View Article : Google Scholar
10	Yilmaz M, Karaaslan M, Polat ME, Tonyali S, Aybal HÇ, Şirin ME, Toprak T, Tunç L, Gratzke C and Miernik A: Is day-case surgery feasible for laser endoscopic enucleation of the prostate? A systematic review. World J Urol. 41:2949–2958. 2023.PubMed/NCBI View Article : Google Scholar
11	McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, Rousseau M, Beahrs JR, Kaminetsky J, et al: Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 195:1529–1538. 2016.PubMed/NCBI View Article : Google Scholar
12	McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, Pliskin M, Beahrs JR, Prall D, Kaminetsky J, et al: Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 206:715–724. 2021.PubMed/NCBI View Article : Google Scholar
13	Dixon CM, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, Larson TR and Mynderse LA: Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 8:207–216. 2016.PubMed/NCBI View Article : Google Scholar
14	Dindo D, Demartines N and Clavien PA: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 240:205–213. 2004.PubMed/NCBI View Article : Google Scholar
15	Miller LE, Chughtai B, Dornbier RA and McVary KT: Surgical reintervention rate after prostatic urethral lift: Systematic review and meta-analysis involving over 2,000 patients. J Urol. 204:1019–1026. 2020.PubMed/NCBI View Article : Google Scholar
16	Sciacqua LV, Vanzulli A, Di Meo R, Pellegrino G, Lavorato R, Vitale G and Carrafiello G: Minimally invasive treatment in benign prostatic hyperplasia (BPH). Technol Cancer Res Treat. 22(15330338231155000)2023.PubMed/NCBI View Article : Google Scholar
17	Yang J, Wu W, Amier Y, Li X, Wan W, Liu C, Zhang Y and Yu X: Efficacy and safety of Water Vapor Thermal Therapy in the treatment of benign prostate hyperplasia: A systematic review and single-arm Meta-analysis. BMC Urol. 23(72)2023.PubMed/NCBI View Article : Google Scholar
18	Bole R, Gopalakrishna A, Kuang R, Alamiri J, Yang DY, Helo S, Ziegelmann MJ and Köhler TS: Comparative postoperative outcomes of rezūm prostate ablation in patients with large versus small glands. J Endourol. 34:778–781. 2020.PubMed/NCBI View Article : Google Scholar
19	Johnston MJ, Noureldin M, Abdelmotagly Y, Paramore L, Gehring T, Nedas TG, Rajkumar G, Emara A and Hindley RG: Rezum water vapour therapy: Promising early outcomes from the first UK series. BJU Int. 126:557–558. 2020.PubMed/NCBI View Article : Google Scholar
20	McVary KT, Holland B and Beahrs JR: Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 23:303–308. 2020.PubMed/NCBI View Article : Google Scholar
21	Babar M, Loloi J, Azhar U, Tang K, Ines M, Singh S, Iqbal N and Ciatto M: Rezum outcomes in relationship to number of injections: Is less more? J Endourol. 37:157–164. 2023.PubMed/NCBI View Article : Google Scholar
22	Bausch K, Zahiti L, Schrutt M, Wetterauer C, Halbeisen FS, Ebbing J and Seifert HH: Water vapor thermal therapy of lower urinary tract symptoms due to benign prostatic obstruction: Efficacy and safety analysis of a real-world cohort of 211 patients. World J Urol. 41:1605–1612. 2023.PubMed/NCBI View Article : Google Scholar
23	Elterman D, Bhojani N, Vannabouathong C, Chughtai B and Zorn KC: Rezūm therapy for ≥80-mL benign prostatic enlargement: A large, multicentre cohort study. BJU Int. 130:522–527. 2022.PubMed/NCBI View Article : Google Scholar
24	Whiting D, Noureldin M, Abdelmotagly Y, Johnston MJ, Brittain J, Rajkumar G, Emara A and Hindley R: Real-world early outcomes and retreatment rates following water vapour ablative therapy for symptomatic benign prostatic hyperplasia. Eur Urol Open Sci. 39:72–78. 2022.PubMed/NCBI View Article : Google Scholar